Supernus Pharmaceuticals | SUPN - Operating Expenses


Supernus Pharmaceuticals reported $1.06B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
ANI Pharmaceuticals USD 637.11M 39.9M Sep/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Canopy Growth CAD 98.74M 23K Jun/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Corcept Therapeutics USD 225.75M 10.9M Sep/2026
Eisai JPY 218.93B 9.33B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Pacira USD 1.18B 995.96M Sep/2026
Perrigo USD 961.4M 670.9M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Xeris Pharmaceuticals USD 86.93M 11.72M Jun/2026